Table 3.
Descriptive information of the GWAS used in the Mendelian randomization study
| UK Biobank21 | PanScan I–III + PanC423 | |
|---|---|---|
| Aim of GWAS | IPFD | PDAC |
| Participants, N | 25,617 | 14,998 |
| (8,275 cases and 6,723 non-cases) | ||
| Age (years) | ||
| Mean (SD) | 64.2 (7.5) | N/A |
| <50; 50–60; 60–70; 70–80; >80, N | N/A | 1,159; 3,088; 5,275; 4,354; 1,122 |
| Female (%) | 51.2 | 45.8 |
| European ancestry (%) | 100 | 100 |
| BMI (kg/m2), mean (SD) | 26.5 (4.3) | N/A |
| IPFD (%), mean (SD) | 10.4 (7.9) | N/A |
IPFD (i.e., fat fraction percentage within the pancreas) was measured on MRI. IPFD, intra-pancreatic fat deposition; PDAC, pancreatic ductal adenocarcinoma; PanScan, Pancreatic Cancer Cohort Consortium; PanC4, Pancreatic Cancer Case-Control Consortium; GWAS, genome-wide association study; SD, standard deviation; BMI, body mass index; N/A, not applicable; MRI, magnetic resonance imaging.